openPR Logo
Press release

Primary Immunodeficiency Diseases Market To Witness High Cagr By 2023

10-10-2019 05:42 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Primary Immunodeficiency Diseases Market To Witness High Cagr

Primary Immunodeficiency Diseases Market: Key Insights

In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and 2023. Developed regions such as Europe and North America are predominantly contributing to the growth witnessed by this market. The consistent approval of novel therapeutic options for primary immunodeficiency diseases (PIDD) and extensive research and development investments by key players are likely to bolster opportunities for the market in the forthcoming years.

View Report: https://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

On the flip side, the absence of proper reimbursement and high cost of therapies will inhibit the market’s growth trajectory to an extent. Nevertheless, with favorable government policies and funding for research and development in biopharma and pharmaceuticals, growth prospects for the market seem quite promising.

TMR expects the global PIDD market to reach US$7.5 bn by the end of 2023, from a valuation of US$4.3 bn in 2014.

Demand for PIDD Treatment Highest in North America and Europe

Collectively accounting for a share of 79.4% in the global PIDD market, North America and Europe emerged as the dominant regional segments in 2014. Among these regions, North America boasted the largest share of 56.2% in 2014, with the U.S. at the fore. As per TMR, the U.S. held over 80.2% of the PIDD market in North America in the same year. The nation is expected to continue demonstrating lucrative opportunities for the PIDD market through the forecast period.

Request a Brochure of Primary Immunodeficiency Diseases Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3137

Over the last couple of years, a persistently increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. This has fuelled the uptake of PIDD therapeutics. However, the growing awareness pertaining to side-effects such as renal failure and allergic reactions frequently associated with the treatment could hamper the market’s growth to an extent.

The primary immunodeficiency diseases market in North America, which stood at US$2.4 bn in 2014, is expected to reach US$4.3 bn by the end of 2023. The market is therefore expected to rise at a CAGR of 6.4% during the period.

In Europe, the market is expected to gain from the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Apart from this, emerging nations in Asia Pacific also exhibit lucrative scope for the expansion of the PIDD market. The increasing willingness among people to spend on novel therapeutics augurs well for sales prospects of the market in Asia Pacific. The region currently holds only a moderate share in the market. However, in the near future the opportunities for sale of PIDD therapeutics in the region will increase considerably.

Rising Uptake of Immunoglobulin (Ig) Replacement Therapy Expected in Near Future

By treatment, stem cell and gene therapy, antibiotic therapy, immunoglobulin (Ig) replacement therapy, and others make the key segments in the global PIDD market. Of these, immunoglobulin replacement has been in use for the treatment of chronic ailments for the past two decades. Due to the recent developments, it is also used for the treatment of partial antibody deficiency and combined immunodeficiencies. The segment therefore emerged dominant in the market in 2014. As per TMR, immunoglobulin replacement therapy will hold on to its position as the market leader through the forecast period.

Request a Sample of Primary Immunodeficiency Diseases Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

Despite, Ig replacement therapy being the most widely accepted treatment among PIDD patients, the use of antibiotics as an adjunct therapy is poised to surge in the near future. Some of the most commonly used antibiotics include penicillin, macrolides, cephalosporins, fluoroquinolones, and tetracyclines.

The demand for stem cell and gene therapy is also expected to increase during the forecast period, which in turn will augment the demand for effective PIDD treatment.

Some of the most prominent companies in the global primary immunodeficiency diseases market are CSL Behring LLC, Baxter International, Inc., Grifols S.A., Octapharma AG, and others.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Immunodeficiency Diseases Market To Witness High Cagr By 2023 here

News-ID: 1846410 • Views: 180

More Releases from Transparency Market Research

Interstitial Cystitis Market to Witness an Outstanding Growth by 2024
Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, with occasional pain in either the lower abdomen, pelvic, or lower back. The patient could experience pain raging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume,
Smart Injury Prevention and Rehabilitation Devices Market Estimated to Flourish …
Smart injury prevention and rehabilitation devices are type of smart medical devices. Smart medical devices are electronic devices with independent processing system. These devices are used to regularly monitor and diagnose various parameters of health and fitness. These are portable electronic devices, have own processing system and memory to store data. These have sensors to diagnose and monitor the activity and exchange data. These devices help physicians to detect various
Surgical Generators Market Projected to Gain Significant Value by 2024
Surgical generators are medical devices capable of producing a cutting and coagulating clinical effect on tissue by the use of alternating current at high frequency. Voltages and currents can vary depending on the desired clinical effect. Surgical generators are also known as power supply or waveform generators. Advances in the past few years have led to electrosurgical generator unit circuitry capable of monitoring changes in voltage that occur during the
Diabetes Gastroparesis Market Size to Expand Significantly by the End of 2024
Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the

All 5 Releases


More Releases for PIDD

Primary Immunodeficiency Diseases Market is expected to reach US$7.5 bn by the e …
As per Transparency Market Research, the global primary immunodeficiency market stood at US$4.3 bn in 2014. Rising at a CAGR of 6.1% between 2015 and 2023, the market is expected to reach US$7.5 bn by the end of 2023. Prevalence of Unmet Medical Needs in Emerging Economies to Create Opportunities for Market’s Growth However, a significant scope for expansion of PIDD diagnostic lies in emerging nations. These nations report a
Primary Immunodeficiency Diseases Market is rising at a CAGR of 6.1% till 2023
As per Transparency Market Research, the global primary immunodeficiency market stood at US$4.3 bn in 2014. Rising at a CAGR of 6.1% between 2015 and 2023, the market is expected to reach US$7.5 bn by the end of 2023. Prevalence of Unmet Medical Needs in Emerging Economies to Create Opportunities for Market’s Growth However, a significant scope for expansion of PIDD diagnostic lies in emerging nations. These nations report a
Primary Immunodeficiency Diseases Market to Rise to US$7.5 bn by 2023
The global primary immunodeficiency diseases market was recorded at US$4.4 bn in 2014. It is expected to exhibit a CAGR of 6.10% within a forecast period from 2015 to 2023. The market could hold a potential value of US$7.6 bn by the end of 2023, according to a research report released by Transparency Market Research. The report, titled “Primary Immunodeficiency Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends
Primary Immunodeficiency Diseases Market is Expected to Rise at a Remarkable CAG …
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Worldwide Primary Immunodeficiency Diseases Market Opportunities: New Born Scree …
Primary immunodeficiency diseases (PIDD) comprise a group of 200+ immune disorders wherein a part of the body’s immune system is either absent or does not function properly. The conditions, which result because of a single-gene defect, are passed down from either one or both parents. In the most common form, PIDDs occur due to problems in DNA that result in a lack of white blood cells, which the immune system